JOENJA Patent Review Extended: FDA's Repetitive Routine
Published Date: 6/20/2025
Notice
Summary
The FDA has officially set the review period for JOENJA, a human drug product, so its patent can be extended. This helps the company get extra time to protect their invention before generic versions can appear. If you’re in the drug business or follow patents, this means a new timeline and potential market impact to watch.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Patent Extension Review Set for JOENJA
The Food and Drug Administration has determined the regulatory review period for JOENJA and published a notice. This lets the patent holder apply to extend a patent that claims this human drug product, giving the company extra time to protect the product before generic versions can appear.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in